Transplant Laboratory, Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany.
Clin Transplant. 2011 Nov-Dec;25(6):905-14. doi: 10.1111/j.1399-0012.2010.01354.x. Epub 2010 Nov 11.
Acute rejection (AR) is an important factor for the development of chronic allograft dysfunction following kidney Tx. Identification of patients who would benefit from closer clinical surveillance to allow individual tailoring of immunosuppression and hence reducing the rate of AR is highly desired. Aim of this study was to investigate the association of pre-transplant alloreactivity and frequency of regulatory T cells (T(regs) ) with AR following living-donor kidney Tx. Peripheral blood mononuclear cells were isolated from 40 patients prior to Tx. T-cell alloreactivity against donor and third-party antigen was assessed by proliferative responses in mixed lymphocyte culture and enzyme linked immunospot technique. Pre-transplant frequency of CD4(+) CD25(+) CD127(low) FoxP3(+) T(regs) was determined by flow cytometry. Experimental data were correlated with occurrence of AR. We found that patients with rejection-free (RF) post-Tx courses showed significantly lower pre-transplant alloreactivity to donor antigen compared to individuals with borderline findings (BL) or AR. For RF patients, the proliferative T-cell responses to third-party antigen were significantly higher than for stimulation with donor cells whereas lymphocytes of the AR group showed the inverse pattern. A significantly higher expression of FoxP3 within the CD4(+) CD25(+) CD127(low) subset for RF and BL compared to the AR group was observed. In conclusion, pre-transplant anti-donor alloreactivity and FoxP3 expression within the CD4(+) CD25(+) CD127(low) subpopulation might prove useful to further define the patient's risk for AR.
急性排斥反应(AR)是肾移植后慢性移植物功能障碍发展的重要因素。确定哪些患者将受益于更密切的临床监测,以便对免疫抑制进行个体化调整,从而降低 AR 发生率,这是非常需要的。本研究旨在探讨移植前同种异体反应性和调节性 T 细胞(Tregs)的频率与活体供肾移植后 AR 的关系。在移植前,从 40 例患者中分离外周血单个核细胞。通过混合淋巴细胞培养和酶联免疫斑点技术评估 T 细胞对供体和第三方抗原的同种异体反应性。通过流式细胞术确定 CD4+CD25+CD127(low)FoxP3+Tregs 的移植前频率。将实验数据与 AR 的发生相关联。我们发现,移植后无排斥(RF)患者的供体抗原移植前同种异体反应性明显低于边缘发现(BL)或 AR 患者。对于 RF 患者,对第三方抗原的增殖 T 细胞反应明显高于与供体细胞刺激相比,而 AR 组的淋巴细胞则表现出相反的模式。与 AR 组相比,RF 和 BL 患者的 CD4+CD25+CD127(low)亚群中 FoxP3 的表达明显更高。总之,移植前的抗供体同种异体反应性和 CD4+CD25+CD127(low)亚群内的 FoxP3 表达可能有助于进一步确定患者发生 AR 的风险。